Sign Out
Clinical use of Follitropin alfa (Follitrope) by the intramuscular or subcutaneous routes may lead to local reactions at the site of injection such as bruising, pain, swelling and itching, the majority of which are mild and transient in nature. Systemic reaction was not observed.
A slightly increased risk of ectopic pregnancy and multiple pregnancies can be seen.
In rare instances, thromboembolism can be associated with hMG/hCG therapy. This may also occur with Follitropin alfa (Follitrope)/hCG therapy.
Most common undesirable effects during the clinical test are headache, abdomen enlarged and displeasure. And fatigue, dizziness, nausea, side abdomen pain, ovarian hyperstimulation and fever are also reported.
View ADR Reporting Link
Continue with Google